NCT06029725

Brief Summary

The appearance of the aging skin is influenced by different factors including by the reduced elasticity and increased laxity of the skin, the decreasing volume as well as pigmentation disorders and dilated vascular markings. Currently, there are different methods available to treat the aging skin. Here, the combined treatment of radiofrequency micro needling (RFMN) and thulium laser has been commonly used in clinical practice. The aim of this clinical study is to investigate the efficacy, patient satisfaction, safety of RFMN and thulium laser treatment in patients with facial, age-related skin laxity, wrinkles, and pigmented lesions.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 8, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

December 15, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

May 21, 2024

Status Verified

May 1, 2024

Enrollment Period

12 months

First QC Date

August 23, 2023

Last Update Submit

May 20, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in wrinkles

    software-assisted evaluation of wrinkles (Vectra(R) Software, Canfield)

    6 months after last treatment session

  • Change in volume

    software-assisted evaluation of volume (Vectra(R) Software, Canfield)

    6 months after last treatment session

  • Change in pigmentation

    software-assisted evaluation of pigmentation (Vectra(R) Software, Canfield)

    6 months after last treatment session

Secondary Outcomes (3)

  • Pain intensity

    10 minutes after starting each treatment session, one treatment session takes 30-50 minutes

  • Adverse Events

    before every treatment session, at every follow-up visit (3 and 6 months post-treatment)

  • Withdrawals due to AE

    before every treatment session, at every follow-up visit (3 and 6 months post-treatment)

Study Arms (2)

RFMN+Thulium

ACTIVE COMPARATOR
Device: radiofrequency microneedling combined with 1927 nm thulium laser

RFMN

ACTIVE COMPARATOR
Device: radiofrequency microneedling monotherapy

Interventions

1. session: radiofrequency microneedling + 1927 nm thulium laser 2. session: 1927 nm thulium laser monotherapy 3. session: 1927 nm thulium laser monotherapy

RFMN+Thulium

1 session: radiofrequency microneedling monotherapy

RFMN

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women from the age of 30 years
  • good general condition, no relevant previous diseases
  • Presence of wrinkles, dermatochalasis on the face, pigment spots, which are an indication for RFMN and thulium laser or comparable methods
  • Cognitive ability and willingness to give consent (informed consent)
  • Be willing and able to attend follow-up visits

You may not qualify if:

  • Age \< 30 years
  • Pregnancy or breastfeeding
  • Excessive subcutaneous fatty tissue under the cheeks
  • Significant scarring of the region to be treated
  • open wounds or lesions of the region to be treated
  • Severe or cystic facial acne
  • Metallic implants in the face or neck region
  • Mental illnesses (psychoses, body perception disorders)
  • Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
  • Fillers in the region to be treated \< 4 weeks prior and during the study period
  • Resurfacing (fractional, ablative, nonablative) of the region of interest \< 2 months prior and during the study period
  • Plastic aesthetic procedures or other surgical procedures \< 6 months prior and during the study period
  • Tendency to have excessive scarring
  • Lack of informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Hamburg-Eppendorf

Hamburg, 20251, Germany

RECRUITING

Related Publications (9)

  • Berneburg M, Plettenberg H, Krutmann J. Photoaging of human skin. Photodermatol Photoimmunol Photomed. 2000 Dec;16(6):239-44. doi: 10.1034/j.1600-0781.2000.160601.x.

    PMID: 11132125BACKGROUND
  • el-Domyati M, el-Ammawi TS, Medhat W, Moawad O, Brennan D, Mahoney MG, Uitto J. Radiofrequency facial rejuvenation: evidence-based effect. J Am Acad Dermatol. 2011 Mar;64(3):524-35. doi: 10.1016/j.jaad.2010.06.045.

    PMID: 21315951BACKGROUND
  • Zelickson BD, Kist D, Bernstein E, Brown DB, Ksenzenko S, Burns J, Kilmer S, Mehregan D, Pope K. Histological and ultrastructural evaluation of the effects of a radiofrequency-based nonablative dermal remodeling device: a pilot study. Arch Dermatol. 2004 Feb;140(2):204-9. doi: 10.1001/archderm.140.2.204.

    PMID: 14967794BACKGROUND
  • Nguyen L, Blessmann M, Schneider SW, Herberger K. Radiofrequency Microneedling for Skin Tightening of the Lower Face, Jawline, and Neck Region. Dermatol Surg. 2022 Dec 1;48(12):1299-1305. doi: 10.1097/DSS.0000000000003607. Epub 2022 Sep 29.

    PMID: 36449871BACKGROUND
  • Wang JV, Christman MP, Feng H, Ferzli G, Jeon H, Geronemus RG. Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser. J Cosmet Dermatol. 2021 Jan;20(1):105-109. doi: 10.1111/jocd.13817. Epub 2020 Nov 11.

    PMID: 33174686BACKGROUND
  • Lu K, Cai S. Efficacy and safety comparison between 1927 nm thulium laser and 2940 nm Er:YAG laser in the treatment of facial atrophic acne scarring: a prospective, simultaneous spilt-face clinical trial. Lasers Med Sci. 2022 Apr;37(3):2025-2031. doi: 10.1007/s10103-021-03465-0. Epub 2021 Nov 26.

    PMID: 34826022BACKGROUND
  • Serra M, Bohnert K, Sadick N. A randomized, single-blind, study evaluating a 755-nm picosecond pulsed Alexandrite laser vs. a non-ablative 1927-nm fractionated thulium laser for the treatment of facial photopigmentation and aging. J Cosmet Laser Ther. 2018 Oct;20(6):335-340. doi: 10.1080/14764172.2018.1493513. Epub 2018 Jul 18.

    PMID: 30019970BACKGROUND
  • Friedman PM, Dover JS, Chapas A, Rahman Z, Ross EV, Kilmer SL, Roberts WE, Sodha P, Stimmel JB, Moncrief MBC, Waibel JS. 1,550 nm Erbium-Doped and 1,927 nm Thulium Nonablative Fractional Laser System: Best Practices and Treatment Setting Recommendations. Dermatol Surg. 2022 Feb 1;48(2):195-200. doi: 10.1097/DSS.0000000000003321.

    PMID: 35050945BACKGROUND
  • Nguyen L, Blessmann M, Schneider SW, Herberger K. Radiofrequency Microneedling With 1927 nm Thulium Laser Versus Radiofrequency Microneedling Monotherapy for Rejuvenation of Photoaged Skin. J Cosmet Dermatol. 2026 Jan;25(1):e70685. doi: 10.1111/jocd.70685.

Central Study Contacts

L Nguyen

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

August 23, 2023

First Posted

September 8, 2023

Study Start

December 15, 2023

Primary Completion

December 1, 2024

Study Completion

March 1, 2025

Last Updated

May 21, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations